Gowling WLG advises IMV Technologies on the acquisition of GenetiRate Inc

2 minute read
23 February 2021

International law firm Gowling WLG (France) has advised IMV Technologies (IMV), the world leader in animal assisted reproduction biotechnologies, on its acquisition of GenetiRate inc., a US-based specialist in automated egg-sorting technology.

The firm's Paris-based corporate and intellectual property lawyers advised longstanding client IMV over this latest phase of growth, supporting on all stages of this complex and multi-jurisdictional transaction. The Gowling WLG team led on negotiations with American lawyers regarding all the legal documentation specific to each jurisdiction, the team also coordinated the deal with various stakeholders.

Generating 85% of turnover internationally, IMV Technologies, a French company, has subsidiaries and manufacturing facilities in Brazil, China, France, India, Italy, the Netherlands, Russia, Scotland, South Africa, and the United States, and an extensive network of distributors in more than 120 countries worldwide. The company operates leading brands in the areas of semen analysis, assisted reproduction, artificial insemination, and veterinary imaging. IMV's Life Sciences division, CryoBio System, manufactures and distributes equipment and supplies for human assisted reproduction and biobanking.

Partner Barbara Jouffa led on corporate aspects alongside senior associate Mathias Briatta, with partner Philippe Rousseau, leading on intellectual property matters.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.